ImmunoGen To Focus Operations On Mivetuximab Soravtansine Development

ImmunoGen IMGN focuses on antibody-drug conjugates for the treatment of cancer and the company said Thursday it will prioritize continued development of “Mivetuximab Soravtansine” targeting solid tumors

Mirvetuximab Soravtansine is a potential new treatment for patients with folate receptor alpha (FRα)-positive cancer.

ImmunoGen shares traded lwoer by 1.5% to $1.90 at time of publication.

Related Links:

Acer Therapeutics Shares Plunge On FDA Complete Response Letter

Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!